We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Biotech company Step Pharma has raised $41.3m (€35m) through the series B financing round to advance its lead cytidine triphosphate synthase 1 (CTPS1) inhibitor STP938 in the clinical development for treating T-cell malignancies.
CTPS1 is a novel target discovered at the Imagine Institute (Paris, France) in rare genetic disease patients exhibiting deficiency in this enzyme involved in CTP nucleotide production